Company news
Xuanzhu Biopharmaceutical Co., Ltd. news
Latest news releases, newest first.
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2026
November 5, 2026
Voluntary announcement phase III clinical study data of Anaprazole Sodium for reflux esophagitis presented at UEG Week 2026PRESENTED at UEG Week 2026
October 21, 2026
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
October 7, 2026
Voluntary announcement unusual price movements
September 17, 2026
2025 Annual report - supplemental information
September 16, 2026
2026 Interim report
September 16, 2026
Voluntary announcement first patient enrolled in phase III clinical trial of anaprazole sodium for helicobacter pylori eradication
June 21, 2026
List of directors and their role and function
June 18, 2026